![]() |
Volumn 16, Issue 1, 2017, Pages
|
Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: Comparison with sitagliptin;Erratum: Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: Comparison with sitagliptin. [Cardiovasc Diabetol. 16, (2017) (8)] DOI: 10.1186/s12933-016-0491-5
|
Author keywords
Dapagliflozin; Sodium glucose co transporter 2 inhibitor; Small dense low density lipoprotein cholesterol; High density lipoprotein 2 cholesterol; Lipoprotein subspecies
|
Indexed keywords
ERRATUM;
ERROR;
|
EID: 85033772700
PISSN: None
EISSN: 14752840
Source Type: Journal
DOI: 10.1186/s12933-016-0491-5 Document Type: Article |
Times cited : (7)
|
References (1)
|